Maintenance of Investigator ’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis

ConclusionsAdult and pediatric participants with mild to moderate AD at baseline who had achieved responder criteria (treatment success) with crisaborole BID during the run-in period maintained response per ISGA with crisaborole QD during the double-blind maintenance period through week 52.Trial RegistrationClinicalTrials.gov: NCT04040192.

http://rd.springer.com/10.1007/s13555-024-01129-9

Source: Dermatology and Therapy - March 28, 2024 Category: Dermatology Source Type: research